MedTrace Logo

Comparing Two Heart Medicines for Fast, Irregular Heartbeat (Atrial Fibrillation)

NCT07706075 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2026-08-03

No results posted yet for this study

Summary

The goal of this clinical trial is to learn whether intravenous verapamil or intravenous metoprolol controls heart rate more effectively in adult patients who arrive at the emergency department with atrial fibrillation and a fast heart rate (rapid ventricular response), but who are otherwise medically stable. Atrial fibrillation with a rapid heart rate is a common emergency, and doctors currently choose between these two standard medicines based on personal preference rather than strong local evidence, since there is limited research on this comparison in Pakistani patients.

The main questions this study aims to answer are:

Does a higher proportion of patients reach a target heart rate of less than 110 beats per minute within 30 minutes with verapamil compared to metoprolol? Which medicine controls the heart rate faster, on average? Are there differences in side effects (such as low blood pressure, slow heart rate, or breathing problems) between the two medicines? Researchers will compare a group of patients receiving verapamil to a group receiving metoprolol to see if one medicine controls the heart rate faster and more safely than the other.

Participants will:

1. Receive either verapamil or metoprolol through an IV, with the dose given according to standard protocols
2. Have their heart rate, blood pressure, and oxygen levels monitored continuously for 30 minutes after the medicine is given
3. Be observed for any side effects during this monitoring period Both medicines used in this study are already standard, guideline-recommended treatments for this condition, so participation will not change or delay the medical care patients would normally receive.

Conditions

  • Atrial Fibrillation (AF)
  • Atrial Fibrillation With Rapid Ventricular Response

Interventions

DRUG

Verapamil Hydrochloride

Intravenous verapamil administered as an initial 5 mg dose over 2 minutes, with an additional 5 mg dose permitted after 15 minutes if target heart rate not achieved, up to a cumulative maximum of 10 mg.

DRUG

Metoprolol tartrate

Intravenous metoprolol tartrate administered as an initial 5 mg dose over 2 minutes, with up to two additional 5 mg doses at 5-minute intervals if target heart rate not achieved, up to a cumulative maximum of 15 mg.

Sponsors & Collaborators

  • Muhammad Ali Javed

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2027-01-01
Primary Completion
2027-07-01
Completion
2027-08-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07706075 on ClinicalTrials.gov